These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30315494)

  • 1. Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective.
    Kozel M; Kočka V; Lisa L; Buděšínský T; Toušek P
    Heart Vessels; 2019 Apr; 34(4):557-563. PubMed ID: 30315494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
    Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
    Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
    Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
    Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update.
    Toušek P; Kočka V; Malý M; Kozel M; Petr R; Hajsl M; Jarkovský J; Lisa L; Buděšínský T; Widimský P
    EuroIntervention; 2016 May; 12(1):23-9. PubMed ID: 27173858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study.
    Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D
    Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study.
    Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M;
    EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.
    Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P
    Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings.
    Seo J; Ahn JM; Hong SJ; Kang DY; Hong SJ; Her AY; Kim YH; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Park DW; Hong MK
    Am J Cardiol; 2020 Jun; 125(11):1624-1630. PubMed ID: 32279841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
    Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
    J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
    Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.